DESTINATION: a Phase 3, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Long-Term Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Published Phase 2 trial data (NEJM, 2023) demonstrated substantial reductions in body weight in some participants exceeding 20% over approximately 48 weeks making retatrutide one of the most potent agents currently in development for obesity and metabolic disease
512,513 ALC significantly improved pain reduction and nerve fiber regeneration in DPN patients treated with ALC
The article says most insurers cover semaglutide only when it is prescribed for type 2 diabetes, and that weight-loss coverage requires documented medical necessity on top of that
It is a fundamental gap in efficacy driven by the dual-receptor mechanism
You should insert your figure here